Open Equity
SEER·

Seer, Inc.: Activist Buyout at $2.45 + Proteomics IP Victory + ITC Investigation Into Competitor

NeutralHealthcare / Life Sciences ToolsMicro CapPublished July 6, 2026
View Our Thesis ↓

SEER — 6 Month Price History

Daily OHLC

Executive Summary

Seer, Inc. (SEER) surged +38% on a confluence of catalysts. The Radoff-JEC Group (activist investors Bradley L. Radoff and Michael Torok) submitted their third non-binding buyout proposal — now at $2.45/share in cash plus contingent value rights (CVR). Separately, Seer won a European patent opposition confirming its proteomics IP, and the U.S. ITC opened an investigation into competitor Nanomics.

Seer is a proteomics technology company providing deep protein sequencing and analysis. Revenue is $16.6M (flat YoY) with $7.1M gross profit (42.6% margin). But SG&A ($42.6M) and R&D ($43.9M) total $86.5M annually, generating massive operating losses. The activist's own filing notes $219M in cash on the balance sheet — the stock trades below net cash.

The board has consistently rejected all three Radoff-JEC proposals as 'highly contingent and non-binding' and defended the company's standalone strategy. An activist proxy contest for board seats is underway.

Neutral. The $2.45 offer provides a floor, IP wins are real, but the board's resistance and $85M annual cash burn mean the path to realization is uncertain.

Business Model & Revenue

Seer, Inc. (NASDAQ: SEER) is a Redwood City, CA proteomics technology company. Its platform enables deep, unbiased protein sequencing and analysis for drug discovery, biomarker identification, and precision medicine. Revenue: $16.6M (FY2025), gross margin: 42.6%. Cash: $219M.

Financial Highlights

MetricFY2025FY2024FY2023
Revenue$16.58M$14.17M$16.66M
Gross Profit$7.06M$8.51M$7.09M
SG&A$42.58M$58.95M$58.53M
R&D$43.87M$53.02M$45.82M
Operating Loss($84.15)M($107.9)M($97.3)M

Cash: $219M (per activist filing). Market Cap: ~$90M (pre-surge). Cash exceeds market cap.

Competitive Landscape

Proteomics is competitive: Thermo Fisher (Orbitrap mass spec), Bruker (timsTOF), Olink (proximity extension assay, acquired by Thermo), and Nautilus Biotechnology. Seer's differentiation is in deep, unbiased proteomic profiling. The European patent win and ITC case against Nanomics validate the IP.

Catalysts

  1. Proxy contest outcome: If Radoff-JEC wins board seats, buyout probability increases significantly.

  2. Binding buyout offer: If the activists convert the proposal to a binding, financed offer, the stock re-rates to $2.45+.

  3. ITC investigation results: A favorable ITC ruling against Nanomics could eliminate a key competitor and validate Seer's IP claims.

  4. Revenue inflection: If Seer signs major customer contracts or partnerships, the growth narrative strengthens.

  5. Strategic acquirer: A major life sciences company (Thermo, Danaher, Agilent) could acquire Seer for the proteomics platform at a premium to the activist offer.

Key Risks

  • Board rejected all three buyout proposals. Proxy contest outcome uncertain.
  • $85M/year cash burn ($42.6M SG&A + $43.9M R&D). ~2.5 year runway at $219M cash.
  • Revenue flat at $16.6M (-0.9% YoY). No revenue growth trajectory.
  • Activist buyout is non-binding and highly contingent. Financing not confirmed.
  • Competitive proteomics market dominated by Thermo Fisher, Bruker, Olink.
  • Pre-revenue commercial stage. Product adoption timeline uncertain.

Our Thesis

The bull case: Seer trades below net cash value ($219M cash vs. ~$90M market cap). The Radoff-JEC $2.45 buyout offer plus CVR represents a 51% premium to pre-surge levels. The European patent win and ITC investigation against Nanomics strengthen Seer's IP moat. Proteomics is a growing market — understanding protein behavior is critical for drug discovery, biomarkers, and precision medicine. If the activist campaign succeeds in gaining board seats, the buyout could become binding.

The bear case: The board rejected all three proposals. Revenue is flat ($16.6M, -0.9% YoY) and the company burns $85M/year on R&D and SG&A. Even with $219M cash, the runway is ~2.5 years without a revenue ramp. The proteomics market is competitive (Thermo Fisher, Bruker, Olink). The buyout is 'highly contingent' — financing is uncertain and the activists have no track record of closing SPAC-style deals.

Neutral because the buyout premium is real but the board's resistance creates deadlock. The $2.45 offer is a valuation anchor, but realization depends on a proxy fight outcome.

Disclaimer: This report is for informational purposes only and does not constitute financial advice. Small-cap, micro-cap, and nano-cap stocks carry significant risk including limited liquidity and higher volatility. Always do your own due diligence before making investment decisions.

Get reports like this delivered free

New small-cap research every week. No paywall, no fluff.